Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data

from GRACEcast - Discussions with the Global Resource for Advancing Cancer Education · host cancerGRACE

Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.

Episode metadata supplied by the publisher feed · Published May 10, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data

0:00 6:03

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GRACEcast - Discussions with the Global Resource for Advancing Cancer Education?

This episode is 6 minutes long.

When was this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode published?

This episode was published on May 10, 2024.

Can I download this GRACEcast - Discussions with the Global Resource for Advancing Cancer Education episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!